SOAT1 and myeloproliferative neoplasm: Targeting JAK-STAT with inhibitors for example ruxolitinib shows therapeutic potential, particularly in myeloproliferative neoplasms and leukemias, though challenges remain in understanding its full regulatory mechanisms and optimizing clinical applications (39).